Cargando…

A randomized phase 2 trial of nintedanib and low-dose cytarabine in elderly patients with acute myeloid leukemia ineligible for intensive chemotherapy

We investigated the safety and efficacy of nintedanib added to low-dose cytarabine (LDAC) in a phase 1/2 study in patients 60 years or older with newly diagnosed or relapsed/refractory (r/r) AML ineligible for intensive chemotherapy. The results of the dose-finding phase 1 part have been previously...

Descripción completa

Detalles Bibliográficos
Autores principales:	Berdel, Andrew F., Koch, Raphael, Gerss, Joachim, Hentrich, Marcus, Peceny, Rudolf, Bartscht, Tobias, Steffen, Björn, Bischoff, Marina, Spiekermann, Karsten, Angenendt, Linus, Mikesch, Jan-Henrik, Kewitz, Tobias, Butterfass-Bahloul, Trude, Serve, Hubert, Lenz, Georg, Berdel, Wolfgang E., Krug, Utz, Schliemann, Christoph
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2022
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9807538/ https://www.ncbi.nlm.nih.gov/pubmed/36399194 http://dx.doi.org/10.1007/s00277-022-05025-0

Ejemplares similares

A Phase I Dose Escalation Study of the Triple Angiokinase Inhibitor Nintedanib Combined with Low-Dose Cytarabine in Elderly Patients with Acute Myeloid Leukemia
por: Schliemann, Christoph, et al.
Publicado: (2016)

RNA-Guided CRISPR-Cas9 System-Mediated Engineering of Acute Myeloid Leukemia Mutations
por: Brabetz, Oliver, et al.
Publicado: (2017)

Magnesium levels and outcome after allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia
por: Angenendt, Linus, et al.
Publicado: (2020)

Amsacrine-based induction therapy in AML patients with cardiac comorbidities: a retrospective single-center analysis
por: Kuron, David, et al.
Publicado: (2023)

Calcitonin receptor‐like (CALCRL) is a marker of stemness and an independent predictor of outcome in pediatric AML
por: Angenendt, Linus, et al.
Publicado: (2021)

MN1–Fli1 oncofusion transforms murine hematopoietic progenitor cells into acute megakaryoblastic leukemia cells
por: Wenge, D V, et al.
Publicado: (2015)

Using stroma-anchoring cytokines to augment ADCC: a phase 1 trial of F16IL2 and BI 836858 for posttransplant AML relapse
por: Berdel, Andrew F., et al.
Publicado: (2022)

First-In-Class CD13-Targeted Tissue Factor tTF-NGR in Patients with Recurrent or Refractory Malignant Tumors: Results of a Phase I Dose-Escalation Study
por: Schliemann, Christoph, et al.
Publicado: (2020)

Characteristics and Outcome of Elderly Patients (>55 Years) with Acute Lymphoblastic Leukemia
por: Wenge, Daniela V., et al.
Publicado: (2022)

Venetoclax plus low-dose cytarabine in Japanese patients with untreated acute myeloid leukaemia ineligible for intensive chemotherapy
por: Yamauchi, Takahiro, et al.
Publicado: (2021)

Ofatumumab with iphosphamide, etoposide and cytarabine for patients with transplantation‐ineligible relapsed and refractory diffuse large B‐cell lymphoma
por: Paszkiewicz‐Kozik, Ewa, et al.
Publicado: (2022)

NG2 proteoglycan as a pericyte target for anticancer therapy by tumor vessel infarction with retargeted tissue factor
por: Brand, Caroline, et al.
Publicado: (2016)

Pretransplant spleen volume and outcome after hematopoietic stem cell transplantation (HSCT) in patients with acute myeloid leukemia (AML)
por: Pohlmann, Alexander, et al.
Publicado: (2023)

Animal Safety, Toxicology, and Pharmacokinetic Studies According to the ICH S9 Guideline for a Novel Fusion Protein tTF-NGR Targeting Procoagulatory Activity into Tumor Vasculature: Are Results Predictive for Humans?
por: Berdel, Wolfgang E., et al.
Publicado: (2020)

Feasibility of Azacitidine Added to Standard Chemotherapy in Older Patients with Acute Myeloid Leukemia — A Randomised SAL Pilot Study
por: Krug, Utz, et al.
Publicado: (2012)

Multiparametric Magnetic Resonance Imaging for Immediate Target Hit Assessment of CD13—Targeted Tissue Factor tTF-NGR in Advanced Malignant Disease
por: Gerwing, Mirjam, et al.
Publicado: (2021)

Validation and refinement of the 2022 European LeukemiaNet genetic risk stratification of acute myeloid leukemia
por: Rausch, Christian, et al.
Publicado: (2023)

P457: COMPLEX CARYOTYPE IS AN INDEPENDENT RISK FACTOR IN TP53-MUTATED AML
por: Rausch, Christian, et al.
Publicado: (2023)

P434: MYELODYSPLASIA-RELATED MUTATIONS IN THE NEW ELN CLASSIFICATION: DOES CLONAL SIZE PLAY A ROLE?
por: Rausch, Christian, et al.
Publicado: (2023)

Venetoclax plus low-dose cytarabine in patients with newly diagnosed acute myeloid leukemia ineligible for intensive chemotherapy: an expanded access study in Japan
por: Asada, Noboru, et al.
Publicado: (2023)

Retrospective, real‐life study of venetoclax plus azacitidine or low‐dose cytarabine in French patients with acute myeloid leukemia ineligible for intensive chemotherapy
por: Laloi, Louise, et al.
Publicado: (2022)

The NPM1 Mutation Type Has No Impact on Survival in Cytogenetically Normal AML
por: Pastore, Friederike, et al.
Publicado: (2014)

New Antifibroblastic Medication in Dermatology: Could Nintedanib Treat Scarring?
por: Cristodor, Patricia Liana, et al.
Publicado: (2022)

The Ineligibility of Antipyrin in Pneumonia
Publicado: (1886)

Long-term survival and polyclonal immunoglobulin reconstitution after allogeneic stem cell transplantation in multiple myeloma
por: Eisfeld, Christine, et al.
Publicado: (2020)

Aminopeptidase N (CD13): Expression, Prognostic Impact, and Use as Therapeutic Target for Tissue Factor Induced Tumor Vascular Infarction in Soft Tissue Sarcoma
por: Kessler, Torsten, et al.
Publicado: (2018)

Genetics of acute myeloid leukemia in the elderly: mutation spectrum and clinical impact in intensively treated patients aged 75 years or older
por: Prassek, Victoria V., et al.
Publicado: (2018)

P446: COMPREHENSIVE CHARACTERIZATION OF DIFFERENTIAL GENE EXPRESSION AND ISOFORM USAGE IN SPLICING FACTOR-MUTATED ACUTE MYELOID LEUKEMIA USING LONG-READ SEQUENCING
por: Thieme, Susanne, et al.
Publicado: (2023)

Prediction of complete remission and survival in acute myeloid leukemia using supervised machine learning
por: Eckardt, Jan-Niklas, et al.
Publicado: (2022)

Unsupervised meta-clustering identifies risk clusters in acute myeloid leukemia based on clinical and genetic profiles
por: Eckardt, Jan-Niklas, et al.
Publicado: (2023)

Integrated RNAi screening identifies the NEDDylation pathway as a synergistic partner of azacytidine in acute myeloid leukemia
por: Klosner, Justine, et al.
Publicado: (2021)

Targeting Tissue Factor to Tumor Vasculature to Induce Tumor Infarction
por: Berdel, Andrew F., et al.
Publicado: (2021)

Outcome of elderly patients with acute promyelocytic leukemia: results of the German Acute Myeloid Leukemia Cooperative Group
por: Lengfelder, Eva, et al.
Publicado: (2012)

Future Options of Molecular-Targeted Therapy in Small Cell Lung Cancer
por: Schulze, Arik Bernard, et al.
Publicado: (2019)

Weekly screening supports terminating nosocomial transmissions of vancomycin-resistant enterococci on an oncologic ward – a retrospective analysis
por: Kampmeier, Stefanie, et al.
Publicado: (2017)

Membrane-interactive lipids as experimental anticancer drugs.
por: Berdel, W. E.
Publicado: (1991)

Unintended Regulatory Caused Early Death—A Difficult Endpoint in Cancer Patient Care and Treatment
por: Berdel, Wolfgang E.
Publicado: (2021)

Activation of Investigator-Initiated Clinical Trials with a Pharmaceutical for Cancer Patients before and after Post-Millennial Changes of Regulations in Germany and Europe
por: Berdel, Wolfgang E.
Publicado: (2022)

Analysis of a novel highly metastatic melanoma cell line identifies osteopontin as a new lymphangiogenic factor
por: LIERSCH, RUEDIGER, et al.
Publicado: (2012)

A clinically applicable gene expression–based score predicts resistance to induction treatment in acute myeloid leukemia
por: Moser, Christian, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_ptca4jmtp85vpdprvks0etsclv